Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | F13A1 | P00488 | 2/20 | 0.47 |
| ▸ | TGM2 | P21980 | 2/20 | 0.47 |
| ▸ | TGM1 | P22735 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29254531 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL23673734 | 0.83 | STS (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL771824 | 0.83 | MEN1 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1487217 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL477255 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL10297355 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL14992459 | 0.81 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL20659413 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL14056986 | 0.80 | TGM2 (0.61) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL477390 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| CN-101500569-A | HIF hydroxylase inhibitors for treatment of anemia of cancer | FIBROGEN INC (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-101490041-A | 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | CN | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | SMN1; SMN2 1708/4885NPC1 3699/4885RAB9A 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.